{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:37:14Z","timestamp":1793824634306,"version":"4.6.1"},"reference-count":98,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","bmn.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.molmed.2024.12.006","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T16:13:06Z","timestamp":1736439186000},"page":"307-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pushing the boundaries: future directions in the management of spinal muscular atrophy"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1431-791X","authenticated-orcid":false,"given":"Fiona","family":"Moultrie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Chiverton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Hatami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Lilien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2024.12.006_bb0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2024.12.006_bb0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0092-8674(95)90461-1","article-title":"The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy","volume":"80","author":"Roy","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2024.12.006_bb0015","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/genes14071377","article-title":"Spinal muscular atrophy treatment in patients identified by newborn screening \u2013 a systematic review","volume":"14","author":"Aragon-Gawinska","year":"2023","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.molmed.2024.12.006_bb0020","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1212\/WNL.40.12.1831","article-title":"Phenotypic heterogeneity of spinal muscular atrophy mapping to chromosome 5q11. 2\u201013.3 (SMA 5q)","volume":"40","author":"Munsat","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2024.12.006_bb0025","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ajhg.2009.08.002","article-title":"A positive modifier of spinal muscular atrophy in the SMN2 gene","volume":"85","author":"Prior","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.molmed.2024.12.006_bb0030","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.molmed.2024.12.006_bb0035","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae267","article-title":"Timing of SMN replacement therapies in mouse models of spinal muscular atrophy: a systematic review and meta-analysis","volume":"6","author":"Chaytow","year":"2024","journal-title":"Brain Commun."},{"key":"10.1016\/j.molmed.2024.12.006_bb0040","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2019.08.017","article-title":"Fetal gene therapy using a single injection of recombinant AAV9 rescued SMA phenotype in mice","volume":"27","author":"Rashnonejad","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2024.12.006_bb0045","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2024.12.006_bb0050","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2024.12.006_bb0055","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5\u2010year update of the NURTURE study","volume":"68","author":"Crawford","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.molmed.2024.12.006_bb0060","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jamapediatrics.2024.0492","article-title":"Clinical effectiveness of newborn screening for spinal muscular atrophy: a nonrandomized controlled trial","volume":"178","author":"Schwartz","year":"2024","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.molmed.2024.12.006_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-99496-2","article-title":"Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium","volume":"11","author":"Boemer","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2024.12.006_bb0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/ijns7020026","article-title":"Massachusetts\u2019 findings from statewide newborn screening for spinal muscular atrophy","volume":"7","author":"Hale","year":"2021","journal-title":"Int. J. Neonatal Screen."},{"key":"10.1016\/j.molmed.2024.12.006_bb0075","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/jmg-2022-108873","article-title":"Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis","volume":"60","author":"Abiusi","year":"2023","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.molmed.2024.12.006_bb0080","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1016\/j.nmd.2023.07.275","article-title":"Newborn screening programs for spinal muscular atrophy worldwide in 2023","volume":"33","author":"Vr\u0161\u010daj","year":"2023","journal-title":"J. Neuromusc. Dis."},{"key":"10.1016\/j.molmed.2024.12.006_bb0085","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s40120-023-00489-2","article-title":"Cost-effectiveness of newborn screening for spinal muscular atrophy in England","volume":"12","author":"Weidlich","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.molmed.2024.12.006_bb0090","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9","article-title":"An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA)","volume":"15","author":"Wirth","year":"2000","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.molmed.2024.12.006_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1095600","article-title":"Technical feasibility of newborn screening for spinal muscular atrophy by next-generation DNA sequencing","volume":"14","author":"Shum","year":"2023","journal-title":"Front. Genet."},{"key":"10.1016\/j.molmed.2024.12.006_bb0100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13023-021-01783-8","article-title":"Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years","volume":"16","author":"Vill","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.molmed.2024.12.006_bb0105","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1093\/hmg\/ddaa146","article-title":"Pre-natal manifestation of systemic developmental abnormalities in spinal muscular atrophy","volume":"29","author":"Motyl","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2024.12.006_bb0110","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/ejhg.2016.195","article-title":"Non-invasive prenatal diagnosis of spinal muscular atrophy by relative haplotype dosage","volume":"25","author":"Parks","year":"2017","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.molmed.2024.12.006_bb0115","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa2314768","article-title":"Nationwide, couple-based genetic carrier screening","volume":"391","author":"Kirk","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2024.12.006_bb0120","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.nmd.2020.10.005","article-title":"Impact of a national population-based carrier-screening program on spinal muscular atrophy births","volume":"30","author":"Aharoni","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.molmed.2024.12.006_bb0125","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/ajo.13206","article-title":"Socioeconomic status and uptake of reproductive carrier screening in Australia","volume":"60","author":"Robson","year":"2020","journal-title":"Aust. N. Z. J. Obstet. Gynaecol."},{"key":"10.1016\/j.molmed.2024.12.006_bb0130","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1007\/s12325-024-02845-6","article-title":"Long-term comparative efficacy and safety of risdiplam and nusinersen in children with type 1 spinal muscular atrophy","volume":"41","author":"Kokaliaris","year":"2024","journal-title":"Adv. Ther."},{"key":"10.1016\/j.molmed.2024.12.006_bb0135","first-page":"82","article-title":"Sequential treatment with nusinersen, Zolgensma\u00ae and risdiplam in a paediatric patient with spinal muscular atrophytype 1: a case report","volume":"42","author":"Bitetti","year":"2023","journal-title":"Acta Myologica"},{"key":"10.1016\/j.molmed.2024.12.006_bb0140","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1080\/03007995.2021.1947216","article-title":"Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1","volume":"37","author":"Bischof","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.molmed.2024.12.006_bb0145","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40120-023-00444-1","article-title":"Risdiplam in patients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH Study","volume":"12","author":"Chiriboga","year":"2023","journal-title":"Neurol Ther."},{"key":"10.1016\/j.molmed.2024.12.006_bb0150","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mus.27375","article-title":"Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1","volume":"64","author":"Oechsel","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.molmed.2024.12.006_bb0155","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1212\/WNL.98.18_supplement.1698","article-title":"Baseline characteristics and initial safety results in RESPOND: a Phase 4 study of nusinersen in children with spinal muscular atrophy (SMA) who received onasemnogene abeparvovec (P18-5.003)","volume":"98","author":"Brandsema","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2024.12.006_bb0160","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/acn3.51889","article-title":"Combination disease-modifying treatment in spinal muscular atrophy: a proposed classification","volume":"10","author":"Proud","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.molmed.2024.12.006_bb0165","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1002\/mus.27648","article-title":"Novel use of nusinersen as a therapeutic bridge to onasemnogene abeparvovec\u2010xioi in a premature neonate with type 1 spinal muscular atrophy","volume":"66","author":"Ferrante","year":"2022","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.molmed.2024.12.006_bb0170","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.molmed.2024.12.006_bb0175","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1212\/WNL.0000000000008207","article-title":"Combination therapy with nusinersen and AVXS-101 in SMA type 1","volume":"93","author":"Lee","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2024.12.006_bb0180","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1212\/WNL.94.15_supplement.4152","article-title":"Combination therapy with nusinersen and AVXS-101: a real-world clinical experience (4152)","volume":"94","author":"Harada","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2024.12.006_bb0185","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.3390\/jcm10235540","article-title":"Combination therapy with nusinersen and onasemnogene abeparvovec-xioi in spinal muscular atrophy type I","volume":"10","author":"Mirea","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.molmed.2024.12.006_bb0190","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejpn.2024.06.004","article-title":"An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies","volume":"51","author":"Giess","year":"2024","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.molmed.2024.12.006_bb0195","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40263-019-00606-6","article-title":"Efficacy and safety of valproic acid for spinal muscular atrophy: a systematic review and meta-analysis","volume":"33","author":"Elshafay","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.molmed.2024.12.006_bb0200","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/jnc.14935","article-title":"Combined treatment with the histone deacetylase inhibitor LBH589 and a splice\u2010switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in spinal muscular atrophy cells","volume":"153","author":"Pagliarini","year":"2020","journal-title":"J. Neurochem."},{"key":"10.1016\/j.molmed.2024.12.006_bb0205","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","volume":"2012","author":"Miller","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.molmed.2024.12.006_bb0210","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/mus.10455","article-title":"Riluzole attenuates spinal muscular atrophy disease progression in a mouse model","volume":"28","author":"Haddad","year":"2003","journal-title":"Muscle Nerve Off. J. Am. Assoc. Electrodiagnostic Med."},{"key":"10.1016\/j.molmed.2024.12.006_bb0215","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1001\/archneur.60.11.1601","article-title":"A Phase 1 trial of riluzole in spinal muscular atrophy","volume":"60","author":"Russman","year":"2003","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.molmed.2024.12.006_bb0220","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/ph3020345","article-title":"Olesoxime (TRO19622): a novel mitochondrial-targeted neuroprotective compound","volume":"3","author":"Bordet","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.molmed.2024.12.006_bb0225","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(17)30085-6","article-title":"Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Bertini","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.molmed.2024.12.006_bb0230","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-510X(01)00632-3","article-title":"A placebo-controlled trial of gabapentin in spinal muscular atrophy","volume":"191","author":"Miller","year":"2001","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.molmed.2024.12.006_bb0235","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/08830738030180080501","article-title":"Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study","volume":"18","author":"Merlini","year":"2003","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.molmed.2024.12.006_bb0240","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/s41598-018-20524-9","article-title":"Blocking extracellular activation of myostatin as a strategy for treating muscle wasting","volume":"8","author":"Pirruccello-Straub","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2024.12.006_bb0245","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209151","article-title":"Safety and efficacy of apitegromab in patients with spinal muscular atrophy types 2 and 3: the Phase 2 TOPAZ study","volume":"102","author":"Crawford","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2024.12.006_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1419791","article-title":"Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study","volume":"15","author":"Crawford","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.molmed.2024.12.006_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910273","article-title":"Taldefgrobep alfa and the Phase 3 RESILIENT trial in spinal muscular atrophy","volume":"25","author":"Servais","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2024.12.006_bb0260","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/j.nmd.2023.07.109","article-title":"P227 MANATEE: GYM329 (RO7204239) in combination with Risdiplam treatment in patients with spinal muscular atrophy (SMA)","volume":"33","author":"Duong","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.molmed.2024.12.006_bb0265","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3390\/cells10030533","article-title":"Antimyostatin treatment in health and disease: the story of great expectations and limited success","volume":"10","author":"Nielsen","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.molmed.2024.12.006_bb0270","doi-asserted-by":"crossref","first-page":"8763","DOI":"10.3390\/ijms25168763","article-title":"Impact of disease severity and disease-modifying therapies on myostatin levels in SMA patients","volume":"25","author":"Mackels","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2024.12.006_bb0275","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nmd.2013.10.011","article-title":"Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study","volume":"24","author":"Kirschner","year":"2014","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.molmed.2024.12.006_bb0280","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s13311-020-01004-3","article-title":"Reldesemtiv in patients with spinal muscular atrophy: a Phase 2 hypothesis-generating study","volume":"18","author":"Rudnicki","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.molmed.2024.12.006_bb0285","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2021-000164","article-title":"Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen","volume":"3","author":"Arnold","year":"2021","journal-title":"BMJ Neurol. Open"},{"key":"10.1016\/j.molmed.2024.12.006_bb0290","doi-asserted-by":"crossref","first-page":"e845","DOI":"10.1212\/WNL.0000000000011230","article-title":"Correlates of fatigability in patients with spinal muscular atrophy","volume":"96","author":"Bartels","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2024.12.006_bb0295","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/WNL.59.4.609","article-title":"Pilot trial of albuterol in spinal muscular atrophy","volume":"59","author":"Kinali","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2024.12.006_bb0300","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.nmd.2008.05.004","article-title":"Daily salbutamol in young patients with SMA type II","volume":"18","author":"Pane","year":"2008","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.molmed.2024.12.006_bb0305","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/jmedgenet-2018-105482","article-title":"Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol","volume":"56","author":"Tiziano","year":"2019","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.molmed.2024.12.006_bb0310","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.clinph.2020.11.044","article-title":"Motor unit reserve capacity in spinal muscular atrophy during fatiguing endurance performance","volume":"132","author":"Habets","year":"2021","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.molmed.2024.12.006_bb0315","article-title":"Randomized double-blind placebo-controlled crossover trial with pyridostigmine in spinal muscular atrophy types 2\u20134","volume":"5","author":"Stam","year":"2023","journal-title":"Brain Commun."},{"key":"10.1016\/j.molmed.2024.12.006_bb0320","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk9109","article-title":"The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis","volume":"16","author":"Skov","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2024.12.006_bb0325","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3233\/JND-170230","article-title":"Analysis of azithromycin monohydrate as a single or a combinatorial therapy in a mouse model of severe spinal muscular atrophy","volume":"4","author":"Osman","year":"2017","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.molmed.2024.12.006_bb0330","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1042\/BST20231116","article-title":"The SMN-ribosome interplay: a new opportunity for spinal muscular atrophy therapies","volume":"52","author":"Sharma","year":"2024","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.molmed.2024.12.006_bb0335","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1741-7015-10-24","article-title":"Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy","volume":"10","author":"Bowerman","year":"2012","journal-title":"BMC Med."},{"key":"10.1016\/j.molmed.2024.12.006_bb0340","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ajhg.2017.01.005","article-title":"Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis","volume":"100","author":"Riessland","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.molmed.2024.12.006_bb0345","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1038\/s41419-017-0086-4","article-title":"Inhibition of autophagy delays motoneuron degeneration and extends lifespan in a mouse model of spinal muscular atrophy","volume":"8","author":"Piras","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.molmed.2024.12.006_bb0350","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.88427","article-title":"ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice","volume":"1","author":"Abera","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.molmed.2024.12.006_bb0355","article-title":"Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine","volume":"2","author":"Chaytow","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.molmed.2024.12.006_bb0360","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nrd3674","article-title":"Epigenetic protein families: a new frontier for drug discovery","volume":"11","author":"Arrowsmith","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molmed.2024.12.006_bb0365","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202317683","article-title":"PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice","volume":"15","author":"Kordala","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.molmed.2024.12.006_bb0370","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.1038\/s41467-024-50095-5","article-title":"Therapeutic strategy for spinal muscular atrophy by combining gene supplementation and genome editing","volume":"15","author":"Hatanaka","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2024.12.006_bb0375","doi-asserted-by":"crossref","DOI":"10.1126\/science.adg6518","article-title":"Base editing rescue of spinal muscular atrophy in cells and in mice","volume":"380","author":"Arbab","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.molmed.2024.12.006_bb0380","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/jnnp-2023-332084","article-title":"Early treatment of type II SMA slows rate of progression of scoliosis","volume":"95","author":"Coratti","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.molmed.2024.12.006_bb0385","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2024.1366943","article-title":"Respiratory morbidity in patients with spinal muscular atrophy \u2013 a changing world in the light of disease-modifying therapies","volume":"12","author":"Lagae","year":"2024","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.molmed.2024.12.006_bb0390","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.nmd.2021.02.011","article-title":"Filling the gaps in knowledge translation: physical therapy recommendations for individuals with spinal muscular atrophy compared to standard of care guidelines","volume":"31","author":"Trenkle","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.molmed.2024.12.006_bb0395","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/WCO.0000000000000974","article-title":"Neuromuscular rehabilitation \u2013 what to do?","volume":"34","author":"Mandarakas","year":"2021","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.molmed.2024.12.006_bb0400","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/14737175.2023.2218549","article-title":"Decision-making and challenges within the evolving treatment algorithm in spinal muscular atrophy: a clinical perspective","volume":"23","author":"Balaji","year":"2023","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.molmed.2024.12.006_bb0405","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12883-023-03136-3","article-title":"The RESISTANT study (Respiratory Muscle Training in Patients with Spinal Muscular Atrophy): study protocol for a randomized controlled trial","volume":"23","author":"Kan-Smits","year":"2023","journal-title":"BMC Neurol."},{"key":"10.1016\/j.molmed.2024.12.006_bb0410","doi-asserted-by":"crossref","first-page":"179","DOI":"10.31083\/j.fbl2706179","article-title":"Physical therapy and nusinersen impact on spinal muscular atrophy rehabilitative outcome","volume":"27","author":"Mirea","year":"2022","journal-title":"Front. Biosci. Landmark"},{"key":"10.1016\/j.molmed.2024.12.006_bb0415","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3390\/life13020449","article-title":"First use of non-invasive spinal cord stimulation in motor rehabilitation of children with spinal muscular atrophy","volume":"13","author":"Novikov","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.molmed.2024.12.006_bb0420","article-title":"Exercise combined with electrotherapy enhances motor function in an adolescent with spinal muscular atrophy type III","volume":"2019","author":"Gobbo","year":"2019","journal-title":"Case Rep. Neurol. Med."},{"key":"10.1016\/j.molmed.2024.12.006_bb0425","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0300244","article-title":"Feasibility and utility of in-home body weight support harness system use in young children treated for spinal muscular atrophy: a single-arm prospective cohort study","volume":"19","author":"Iammarino","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2024.12.006_bb0430","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12984-022-01055-x","article-title":"Effects of ATLAS 2030 gait exoskeleton on strength and range of motion in children with spinal muscular atrophy II: a case series","volume":"19","author":"Cumplido-Trasmonte","year":"2022","journal-title":"J. Neuro Eng. Rehabil."},{"key":"10.1016\/j.molmed.2024.12.006_bb0435","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s13023-021-01928-9","article-title":"Cybernic treatment with wearable cyborg Hybrid Assistive Limb (HAL) improves ambulatory function in patients with slowly progressive rare neuromuscular diseases: a multicentre, randomised, controlled crossover trial for efficacy and safety (NCY-3001)","volume":"16","author":"Nakajima","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.molmed.2024.12.006_bb0440","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1002\/acn3.52213","article-title":"Onasemnogene\u2013abeparvovec administration to premature infants with spinal muscular atrophy","volume":"11","author":"Brown","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.molmed.2024.12.006_bb0445","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/acn3.51281","article-title":"Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study","volume":"8","author":"Annoussamy","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.molmed.2024.12.006_bb0450","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2024.12.006_bb0455","first-page":"S210","article-title":"Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): end of study results from the phase 3 CHERISH study","volume":"27","author":"Mercuri","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.molmed.2024.12.006_bb0460","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.S25.001","article-title":"Nusinersen in infants who initiate treatment in a presymptomatic stage of spinal muscular atrophy (SMA): interim efficacy and safety results from the phase 2 NURTURE study (S25. 001)","volume":"92","author":"De Vivo","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2024.12.006_bb0465","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2024.12.006_bb0470","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.molmed.2024.12.006_bb0475","first-page":"A10","article-title":"S12 Onasemnogene abeparvovec gene therapy for spinal muscular atrophy type 1: phase 3 study (STR1VE-US)","volume":"76","author":"Day","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.molmed.2024.12.006_bb0480","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls","volume":"385","author":"Darras","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2024.12.006_bb0485","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.molmed.2024.12.006_bb0490","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1212\/WNL.0000000000205694","article-title":"RAINBOWFISH: primary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA)(S37. 006)","volume":"102","author":"Servais","year":"2024","journal-title":"Neurology"}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491424003393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491424003393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T04:53:35Z","timestamp":1744433615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491424003393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1471491424003393"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2024.12.006","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pushing the boundaries: future directions in the management of spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2024.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}